Matches in Wikidata for { <http://www.wikidata.org/entity/Q92948285> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q92948285 description "article scientifique publié en 2019" @default.
- Q92948285 description "artículu científicu espublizáu en payares de 2019" @default.
- Q92948285 description "scientific article published on 01 November 2019" @default.
- Q92948285 description "wetenschappelijk artikel" @default.
- Q92948285 description "наукова стаття, опублікована 1 листопада 2019" @default.
- Q92948285 name "All-oral (vinorelbin plus capecitabine) combination regimen might be preferable to oral vinoreline or weeky paclitaxel in estrogen receptor-positive, HER2-negative patients with visceral metastasis" @default.
- Q92948285 name "All-oral (vinorelbin plus capecitabine) combination regimen might be preferable to oral vinoreline or weeky paclitaxel in estrogen receptor-positive, HER2-negative patients with visceral metastasis" @default.
- Q92948285 type Item @default.
- Q92948285 label "All-oral (vinorelbin plus capecitabine) combination regimen might be preferable to oral vinoreline or weeky paclitaxel in estrogen receptor-positive, HER2-negative patients with visceral metastasis" @default.
- Q92948285 label "All-oral (vinorelbin plus capecitabine) combination regimen might be preferable to oral vinoreline or weeky paclitaxel in estrogen receptor-positive, HER2-negative patients with visceral metastasis" @default.
- Q92948285 prefLabel "All-oral (vinorelbin plus capecitabine) combination regimen might be preferable to oral vinoreline or weeky paclitaxel in estrogen receptor-positive, HER2-negative patients with visceral metastasis" @default.
- Q92948285 prefLabel "All-oral (vinorelbin plus capecitabine) combination regimen might be preferable to oral vinoreline or weeky paclitaxel in estrogen receptor-positive, HER2-negative patients with visceral metastasis" @default.
- Q92948285 P1433 Q92948285-D785D100-FDAA-40C8-90E8-46D284B21D58 @default.
- Q92948285 P1476 Q92948285-FC3E251B-66B9-48EC-AB33-7453D025FFBB @default.
- Q92948285 P304 Q92948285-2EB4FAB8-2865-4EE5-987F-7C422E0FC061 @default.
- Q92948285 P31 Q92948285-D762211B-3809-46DE-AB5E-63BAB66C0762 @default.
- Q92948285 P433 Q92948285-205ADE17-7A82-4DA8-A272-2696ABD0D99B @default.
- Q92948285 P478 Q92948285-05F3B930-8CE4-4F61-AC5F-59FCC82F4895 @default.
- Q92948285 P50 Q92948285-C9DD3130-F83B-4882-AA56-9FD40551BF7B @default.
- Q92948285 P577 Q92948285-3DD3CB2E-04A4-4AD8-A7AB-FB2D11D7FC7A @default.
- Q92948285 P698 Q92948285-13C45BC9-29F3-45B8-84B3-8B725CC64722 @default.
- Q92948285 P921 Q92948285-EB66BC2C-A556-4C55-97F7-3629F75666F0 @default.
- Q92948285 P921 Q92948285-F4E7A1C8-B35B-4422-AAF8-03E530FD819D @default.
- Q92948285 P698 31983138 @default.
- Q92948285 P1433 Q27721148 @default.
- Q92948285 P1476 "All-oral (vinorelbin plus capecitabine) combination regimen might be preferable to oral vinoreline or weeky paclitaxel in estrogen receptor-positive, HER2-negative patients with visceral metastasis" @default.
- Q92948285 P304 "2578" @default.
- Q92948285 P31 Q13442814 @default.
- Q92948285 P433 "6" @default.
- Q92948285 P478 "24" @default.
- Q92948285 P50 Q87657419 @default.
- Q92948285 P577 "2019-11-01T00:00:00Z" @default.
- Q92948285 P698 "31983138" @default.
- Q92948285 P921 Q420207 @default.
- Q92948285 P921 Q423762 @default.